Cancer is a complex collection of diseases characterized by uncontrolled cell growth, and its management is a pillar of modern pharmacotherapy. For pharmacists, a foundational understanding of cancer pathophysiology, treatment modalities, and supportive care is essential for providing safe and effective patient-centered care. This quiz for PharmD students will test your knowledge of the core principles of oncology, from the cellular level to the application of complex therapeutics.
1. A key characteristic of a cancer cell that distinguishes it from a normal cell is its:
- Ability to undergo programmed cell death (apoptosis).
- Uncontrolled proliferation and immortality.
- Adherence to normal cell cycle checkpoints.
- Limited number of cell divisions.
Answer: Uncontrolled proliferation and immortality.
2. A gene that, when mutated or overexpressed, can contribute to the development of cancer is known as a(n):
- Tumor suppressor gene
- DNA repair gene
- Oncogene
- Housekeeping gene
Answer: Oncogene
3. A “tumor suppressor gene,” like p53 or BRCA1, normally functions to:
- Promote cell division.
- Regulate the cell cycle and promote apoptosis if DNA damage is irreparable.
- Stimulate the growth of new blood vessels.
- Cause the cell to become immortal.
Answer: Regulate the cell cycle and promote apoptosis if DNA damage is irreparable.
4. The process by which a tumor develops its own blood supply to support its growth is called:
- Metastasis
- Apoptosis
- Angiogenesis
- Differentiation
Answer: Angiogenesis
5. “Metastasis” is the process by which cancer cells:
- Stop dividing.
- Spread from the primary tumor to distant sites in the body.
- Repair their own DNA damage.
- Undergo programmed cell death.
Answer: Spread from the primary tumor to distant sites in the body.
6. Which of the following is a major modality for cancer treatment?
- Surgery
- Radiation Therapy
- Systemic Therapy (e.g., chemotherapy, immunotherapy)
- All of the above
Answer: All of the above
7. Traditional “cytotoxic” chemotherapy agents primarily work by:
- Targeting specific mutations only found in cancer cells.
- Killing rapidly dividing cells, including both cancer cells and certain normal cells.
- Stimulating the patient’s immune system to fight the cancer.
- Blocking hormone receptors.
Answer: Killing rapidly dividing cells, including both cancer cells and certain normal cells.
8. Myelosuppression is a common side effect of many traditional chemotherapies. This affects which cells in the body?
- Nerve cells in the brain.
- Muscle cells in the heart.
- Blood-forming cells in the bone marrow.
- Epithelial cells in the gut.
Answer: Blood-forming cells in the bone marrow.
9. A patient receiving highly emetogenic (nausea-inducing) chemotherapy would be prophylactically treated with:
- An antibiotic.
- An opioid analgesic.
- A combination of antiemetics, such as a 5-HT3 antagonist.
- A laxative.
Answer: A combination of antiemetics, such as a 5-HT3 antagonist.
10. “Targeted therapy” differs from traditional chemotherapy in that it:
- Is designed to interfere with specific molecules (targets) involved in cancer cell growth and survival.
- Has no side effects.
- Is effective for all types of cancer.
- Is always administered intravenously.
Answer: Is designed to interfere with specific molecules (targets) involved in cancer cell growth and survival.
11. A drug with a name ending in “-mab” is a ________, while a drug ending in “-ib” is typically a ________.
- Small molecule inhibitor; monoclonal antibody
- Monoclonal antibody; small molecule inhibitor
- Cytotoxic agent; hormonal agent
- Hormonal agent; cytotoxic agent
Answer: Monoclonal antibody; small molecule inhibitor
12. The primary principle of “immunotherapy” for cancer is to:
- Directly poison the cancer cells.
- Harness the patient’s own immune system to recognize and attack cancer cells.
- Inhibit DNA replication.
- Block the formation of new blood vessels.
Answer: Harness the patient’s own immune system to recognize and attack cancer cells.
13. Immune checkpoint inhibitors, like pembrolizumab, work by:
- Blocking the “brakes” on the immune system, allowing T-cells to be more active against tumors.
- Stimulating the production of red blood cells.
- Directly binding to and killing cancer cells.
- Inhibiting a specific tyrosine kinase.
Answer: Blocking the “brakes” on the immune system, allowing T-cells to be more active against tumors.
14. “Hormone therapy” is a mainstay of treatment for cancers that are sensitive to hormones, such as:
- Certain types of breast and prostate cancer.
- Lung cancer.
- Melanoma.
- Leukemia.
Answer: Certain types of breast and prostate cancer.
15. Aromatase inhibitors are used in postmenopausal women with ER-positive breast cancer to:
- Block the estrogen receptor directly.
- Prevent the conversion of androgens to estrogens in peripheral tissues.
- Increase the production of estrogen by the ovaries.
- Stimulate the growth of the tumor.
Answer: Prevent the conversion of androgens to estrogens in peripheral tissues.
16. “Adjuvant” chemotherapy is given ________ the primary treatment (like surgery) to eliminate micrometastatic disease.
- Before
- After
- Instead of
- During
Answer: After
17. “Neoadjuvant” chemotherapy is given ________ the primary treatment to shrink the tumor.
- Before
- After
- Instead of
- During
Answer: Before
18. “Palliative” chemotherapy is given with the primary intent to:
- Cure the cancer.
- Relieve symptoms and improve quality of life when a cure is not possible.
- Prevent cancer from developing.
- Be used as a diagnostic tool.
Answer: Relieve symptoms and improve quality of life when a cure is not possible.
19. A “complete response” (CR) to cancer therapy means:
- The tumor has shrunk by at least 50%.
- The disappearance of all signs and symptoms of the cancer.
- The patient feels better.
- The tumor has stopped growing but is still present.
Answer: The disappearance of all signs and symptoms of the cancer.
20. A pharmacist’s knowledge of “pharmacogenomics” is critical in oncology because:
- The presence of a specific tumor mutation is often required for a targeted therapy to be effective.
- It helps predict the cost of treatment.
- All cancer patients have the same genetic makeup.
- It is not a relevant field in cancer care.
Answer: The presence of a specific tumor mutation is often required for a targeted therapy to be effective.
21. A “nadir” refers to the lowest point that ________ reach after a cycle of chemotherapy.
- Tumor markers
- Blood cell counts
- The patient’s weight
- The patient’s pain score
Answer: Blood cell counts
22. “Febrile neutropenia” is an oncologic emergency that requires immediate:
- Administration of an antiemetic.
- A blood transfusion.
- Initiation of empiric broad-spectrum antibiotics.
- A reduction in pain medication.
Answer: Initiation of empiric broad-spectrum antibiotics.
23. A key role for a pharmacist in supportive care is managing “CINV.” This acronym stands for:
- Cancer-Induced Nausea and Vomiting.
- Chemotherapy-Induced Nausea and Vomiting.
- Cancer-Induced Neutropenia and Vomiting.
- Chemotherapy-Induced Neuropathic Vomiting.
Answer: Chemotherapy-Induced Nausea and Vomiting.
24. A pharmacist working in an oncology “practice setting” is most likely to be found in a(n):
- Hospital or outpatient infusion center.
- Standard community pharmacy.
- Mail-order pharmacy.
- Supermarket pharmacy.
Answer: Hospital or outpatient infusion center.
25. A key “leadership” role for an oncology pharmacist is:
- To advocate for evidence-based and safe medication use protocols within their institution.
- To make all final treatment decisions for the patient.
- To manage the hospital’s overall budget.
- To perform surgery.
Answer: To advocate for evidence-based and safe medication use protocols within their institution.
26. The “financials” of oncology are a major concern due to the high cost of new therapies. A pharmacist can help by:
- Connecting patients with financial assistance programs.
- Recommending less effective, cheaper alternatives.
- Ignoring the cost of treatment.
- Refusing to dispense expensive medications.
Answer: Connecting patients with financial assistance programs.
27. A “business plan” for a new oncology pharmacy service would need to justify the pharmacist’s role by demonstrating:
- A positive impact on patient safety and outcomes.
- The high number of prescriptions that will be dispensed.
- The popularity of the service among nurses.
- A detailed marketing plan only.
Answer: A positive impact on patient safety and outcomes.
28. An “analytics and reporting system” is a critical tool for an oncology pharmacy to:
- Track adherence to supportive care guidelines and monitor adverse drug events.
- Order office supplies.
- Schedule patient appointments.
- Communicate with the media.
Answer: Track adherence to supportive care guidelines and monitor adverse drug events.
29. A “Clinical Decision Support” system in an EHR is vital for oncology because it can:
- Alert a prescriber to a dose that exceeds the maximum lifetime cumulative dose for a cardiotoxic agent like doxorubicin.
- Remind the team to perform required lab monitoring.
- Check for complex drug interactions with oral chemotherapy agents.
- All of the above.
Answer: All of the above.
30. The “human factors” principle of designing for safety is extremely important in oncology due to the:
- Low risk of the medications used.
- High potential for catastrophic harm from a medication error.
- Simplicity of the dosing regimens.
- Lack of any potential for errors.
Answer: High potential for catastrophic harm from a medication error.
31. The “regulation” of chemotherapy preparation is governed by standards like USP <800> to ensure:
- The safety of the patient receiving the drug.
- The safety of the healthcare worker handling the hazardous drug.
- The stability of the final product.
- All of the above.
Answer: All of the above.
32. The pharmacist’s “advocacy” skills are used when:
- Negotiating with a payer for an off-label use of a drug that is supported by clinical evidence.
- A patient needs education on how to manage their side effects.
- A new chemotherapy order needs to be verified.
- All of the above.
Answer: All of the above.
33. The “services” provided by an oncology pharmacist include:
- Patient education.
- Medication therapy management.
- Supportive care management.
- All of the above.
Answer: All of the above.
34. The “policy” of requiring a “companion diagnostic” test before a targeted therapy can be used is an example of:
- A barrier to care.
- A key component of personalized medicine.
- A cost-saving measure only.
- An outdated practice.
Answer: A key component of personalized medicine.
35. A “negotiation” between a pharmacist and an oncologist might occur when:
- The pharmacist recommends a dose adjustment based on the patient’s renal function, and the oncologist has a different opinion.
- The pharmacist is counseling the patient.
- The pharmacist is preparing an IV bag.
- The pharmacist is checking the patient’s allergies.
Answer: The pharmacist is recommending a dose adjustment based on the patient’s renal function, and the oncologist has a different opinion.
36. A pharmacist’s knowledge of “DNA repair mechanisms” is critical for understanding how which class of drugs works?
- Monoclonal antibodies
- PARP inhibitors.
- Aromatase inhibitors
- Immune checkpoint inhibitors
Answer: PARP inhibitors.
37. The “forging ahead” mindset means viewing the future of oncology pharmacy as:
- Increasingly integrated with genomics, informatics, and novel therapeutics.
- A static field with few changes.
- A role that will be replaced by automation.
- Focused only on dispensing.
Answer: Increasingly integrated with genomics, informatics, and novel therapeutics.
38. “Tumor Lysis Syndrome” is an oncologic emergency caused by the rapid breakdown of cancer cells. A pharmacist would be involved in managing this with:
- Aggressive hydration and uric acid-lowering agents like allopurinol.
- Broad-spectrum antibiotics.
- High-dose opioids.
- Antiemetics.
Answer: Aggressive hydration and uric acid-lowering agents like allopurinol.
39. A pharmacist’s expertise in _________ is crucial for managing the many drug interactions associated with oral chemotherapy agents, many of which are CYP3A4 substrates.
- Pharmacokinetics
- Health policy
- Medicinal chemistry
- Sterile compounding
Answer: Pharmacokinetics
40. The development of “CAR-T cell” therapy is an example of a(n):
- New type of oral chemotherapy.
- Advanced immunotherapy that involves genetically engineering a patient’s own T-cells.
- Small molecule inhibitor.
- Type of hormone therapy.
Answer: Advanced immunotherapy that involves genetically engineering a patient’s own T-cells.
41. The principle of “evidence evaluation” is a daily activity for an oncology pharmacist because:
- The field of oncology is rapidly changing, with new clinical trial data published constantly.
- The treatment guidelines never change.
- All cancer drugs are equally effective.
- It is not an important skill.
Answer: The field of oncology is rapidly changing, with new clinical trial data published constantly.
42. A key “health disparity” in cancer care is:
- Unequal access to screening, diagnosis, and advanced treatments among different racial and socioeconomic groups.
- The fact that cancer affects all populations equally.
- A higher survival rate for all cancers in minority populations.
- The low cost of cancer care.
Answer: Unequal access to screening, diagnosis, and advanced treatments among different racial and socioeconomic groups.
43. A pharmacist’s communication with a “caregiver” of a cancer patient should include:
- Education on how to manage side effects at home.
- Instructions on when to call the clinic.
- Emotional support and connection to resources.
- All of the above.
Answer: All of the above.
44. The use of “molecular biology techniques” is the foundation for:
- Identifying the specific genetic mutations in a tumor that can be targeted with drugs.
- All surgical procedures.
- The management of nausea.
- The counseling of cancer patients.
Answer: Identifying the specific genetic mutations in a tumor that can be targeted with drugs.
45. “Pancytopenia” is a term for the suppression of:
- Only white blood cells.
- Only red blood cells.
- Only platelets.
- All three major blood cell lines (red cells, white cells, and platelets).
Answer: All three major blood cell lines (red cells, white cells, and platelets).
46. Which of the following is an example of a “human resources” issue in an oncology pharmacy?
- Ensuring all staff have documented competency for safely handling hazardous drugs.
- The price of a new chemotherapy agent.
- The design of a clinical trial.
- The brand of computer used in the pharmacy.
Answer: Ensuring all staff have documented competency for safely handling hazardous drugs.
47. A “drug class review” conducted by a P&T committee for a group of new PARP inhibitors is an example of:
- An evidence-based process to make formulary decisions.
- A marketing presentation.
- A basic dispensing task.
- A legal proceeding.
Answer: An evidence-based process to make formulary decisions.
48. An “Electronic Health Record” (EHR) is critical for the safe administration of complex chemotherapy regimens because it allows for:
- The use of standardized, evidence-based electronic order sets.
- Clear documentation of administration times and dates.
- Tracking of cumulative drug doses.
- All of the above.
Answer: All of the above.
49. A key “geriatric sensitivity” principle in oncology is that:
- Older adults should not receive chemotherapy.
- Older adults may have a reduced ability to tolerate the toxicities of chemotherapy, requiring careful assessment and dose adjustments.
- Chronological age is the only factor to consider when choosing a regimen.
- All older adults have the same treatment goals.
Answer: Older adults may have a reduced ability to tolerate the toxicities of chemotherapy, requiring careful assessment and dose adjustments.
50. The ultimate principle of an oncology pharmacist’s role is to:
- Act as a vital member of the interprofessional team to optimize the safety and efficacy of cancer therapy for every patient.
- Focus only on the dispensing of medications.
- Defer all clinical decisions to the oncologist.
- Work to reduce the cost of care, even if it means using less effective treatments.
Answer: Act as a vital member of the interprofessional team to optimize the safety and efficacy of cancer therapy for every patient.
